ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
” CASGEVY¢ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain ” ” Clinical trials ongoing for next generation CAR T product candidates, CTX112¢ and CTX131¢...
CRISPR Therapeutics to Present at Citi 2024 Virtual Oncology Leadership Summit
- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and...
Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:...
After resigning from her role as chief medical officer at CRISPR Therapeutics, Phuong Khanh Morrow, M.D., is taking on the role of head of the oncology therapeutic area unit at Takeda.
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder